Get the essential updates shaping the future of pharma manufacturing and compliance. Subscribe to Pharmaceutical Technology and never miss an industry breakthrough.

Subscribe

Related Content

Silver Spring, MD, USA - June 25, 2022: The FDA White Oak Campus, headquarters of the United States Food and Drug Administration, a federal agency of the Department of Health and Human Services (HHS) | © Tada Images - stock.adobe.com (521699065)

What Trutakna's FDA Approval Means for Specialty Biologics

ByStephen Appezzato,Zachary Zubulake

July 7th 2026

The EMA is accelerating the approval of daraxonrasib through a phased assessment, which could reshape submission planning in the EU.

Daraxonrasib Review Signals Shift in EU Drug Assessment Rules

ByZachary Zubulake

July 7th 2026

Modern digital illustration depicting supply chain challenges in pharmaceutical and medical logistics with interconnected icons | Image Credit: ©KHAN VECTOR CO. -stock.adobe.com

The Role of Standards in the Drug Supply Chain

ByGabriela Grasa Mannino,Susan Haigney

July 7th 2026

Medical worker touch virtual medical revolution and advance of technology Artificial Intelligence,AI Deep Learning for medical research,Transformation of innovation and technology for future Health | Image Credit: ©Toowongsa -stock.adobe.com

What FDA's AI Warning Letter Tells Us About GMP Accountability

ByGourav Pandey,Svyatoslav Borshchenko

July 6th 2026

The FDA finalized a rule standardizing the NDC to a uniform, 12-digit format

Preparing for Pharma’s “Y2K Moment”: What the Shift to a 12-Digit NDC Means for Manufacturers

ByMatt Sample

July 2nd 2026

The Future State of Computer Validation, Part II: Increasing the Efficiency of Computer Validation Practices

Articles in this issue

Related Content

What Trutakna's FDA Approval Means for Specialty Biologics

Daraxonrasib Review Signals Shift in EU Drug Assessment Rules

The Role of Standards in the Drug Supply Chain

What FDA's AI Warning Letter Tells Us About GMP Accountability

Preparing for Pharma’s “Y2K Moment”: What the Shift to a 12-Digit NDC Means for Manufacturers

Trending on Pharmaceutical Technology

What FDA's AI Warning Letter Tells Us About GMP Accountability

Daraxonrasib Review Signals Shift in EU Drug Assessment Rules

Why Are Drugmakers Racing to Acquire ADC Payload Platforms?

What Trutakna's FDA Approval Means for Specialty Biologics

The Role of Standards in the Drug Supply Chain